All In Biotech

NDA 019887 · Fresenius Kabi USA

Nebupent

Pentamidine Isethionate · Inhalation

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 16, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Jun 15, 1989

Approved uses

2

Original approval plus efficacy supplements

Registered trials

48

13 Phase 3, 2 recruiting

FAERS reports

1,217

1,086 serious, 217 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 15, 2024.

INDICATIONS AND USAGE: NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 5, 1996 Supplement 2 · Efficacy
  • Jun 15, 1989 Original approval · Type 3 - New Dosage Form · priority review
2 products under this application
  • NEBUPENT · PENTAMIDINE ISETHIONATE 600MG/VIAL · FOR SOLUTION, INHALATION · Discontinued
  • NEBUPENT · PENTAMIDINE ISETHIONATE 300MG/VIAL · FOR SOLUTION, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Pentamidine Isethionate" as an intervention, any sponsor and status, largest first.

All 48 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia135
  • pyrexia134
  • off label use83
  • diarrhoea79
  • neutropenia78
  • aplastic anaemia77
  • pneumonia62
  • sepsis58
  • mucosal inflammation57
  • pancytopenia53
  • vomiting53
  • nausea52

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200412
200520
200646
200746
200846
200967
2010108
201166
201251
201327
201417
201527
201639
201737
201828
201956
202085
202193
202297
202349
202488
202572
202640

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Nebupent* (Pentamidine Isethionate*) · HCPCS J2545

2024 spending

$138K

Beneficiaries

486

1,802 claims

Per beneficiary

$284

2024 ASP limit $77.67 per unit

View as table
YearSpending
2020$144,508
2021$150,087
2022$172,132
2023$158,306
2024$137,942

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 27 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.